{"id":350,"date":"2014-03-29T10:41:09","date_gmt":"2014-03-29T10:41:09","guid":{"rendered":"http:\/\/stg-blogs.bmj.com\/jnnp\/?p=350"},"modified":"2014-03-29T10:41:44","modified_gmt":"2014-03-29T10:41:44","slug":"are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms","status":"publish","type":"post","link":"https:\/\/stg-blogs.bmj.com\/jnnp\/2014\/03\/29\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\/","title":{"rendered":"Are the sphingosine wars beginning?: Ponesimod-Promising new oral agent for RRMS"},"content":{"rendered":"<p>Another oral agent has shown promise in a phase IIb trial for relapsing-remitting MS.\u00a0 Ponesimod, a selective s<span class=\"irc_su\" dir=\"ltr\" style=\"text-align: left\">phingosine 1-Phosphate Receptor 1 Agonist, reduced disease burden and activity as assessed by MRI and clinical measures (annualized relapse rates).\u00a0\u00a0 Safety and tolerability\u00a0 were also assessed and proven to be good. \u00a0 Larger trials are required to confirm the therapeutic utility of ponesimod in RRMS,\u00a0 although choice is always good.\u00a0 Read more in JNNP:<br \/>\n<\/span><\/p>\n<p><!--[if gte mso 9]&gt;--><\/p>\n<p><!--[if gte mso 9]&gt;--><\/p>\n<p>&nbsp;<\/p>\n<p class=\"MsoNormal\"><b><i><span style=\"font-size: 14.0pt;font-family: 'Times New Roman','serif'\">Olsson T, Boster A, Fern\u00e1ndez O, Freedman MS, Pozzilli C, Bach D, Berkani O, Mueller MS, Sidorenko T, Radue EW, Melanson M. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24659797\"><span style=\"color: #00006f;text-decoration: none\">Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.<\/span><\/a> J Neurol Neurosurg Psychiatry. 2014 Mar 21. doi: 10.1136\/jnnp-2013-307282. <\/span><\/i><\/b><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"irc_mut\" id=\"irc_mi\" style=\"margin-top: 0px\" alt=\"\" src=\"http:\/\/jpet.aspetjournals.org\/content\/337\/2\/547\/F1.large.jpg\" width=\"189\" height=\"189\" \/><\/p>\n<p>Ponesimod structure- Are the sphingosine wars beginning?<!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Another oral agent has shown promise in a phase IIb trial for relapsing-remitting MS.\u00a0 Ponesimod, a selective sphingosine 1-Phosphate Receptor 1 Agonist, reduced disease burden and activity as assessed by MRI and clinical measures (annualized relapse rates).\u00a0\u00a0 Safety and tolerability\u00a0 were also assessed and proven to be good. \u00a0 Larger trials are required to confirm [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/stg-blogs.bmj.com\/jnnp\/2014\/03\/29\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-350","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/stg-blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/posts\/350","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stg-blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stg-blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/comments?post=350"}],"version-history":[{"count":0,"href":"https:\/\/stg-blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/posts\/350\/revisions"}],"wp:attachment":[{"href":"https:\/\/stg-blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/media?parent=350"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/categories?post=350"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/tags?post=350"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}